Abstract Details

Title Association Between Hippocampal Volume on Portable Magnetic Resonance Imaging and Cognitive Ability in Patients with Cardiovascular Risk Factors

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 3-020

Objective To assess the relationship between hippocampal volume and cognitive ability in patients with cardiovascular risk factors.

Background Decreasing hippocampal volume has been associated with cognitive decline in patients with neurodegenerative disease or advanced age. Although cardiovascular risk factors have been associated with increased risk of cognitive impairment, the relationship between hippocampal volume and cognitive ability in patients with these risk factors is underexplored.

Design/Methods Patients with at least one cardiovascular risk factor presenting to an emergency department between December 2021 and July 2024 were recruited to receive a fluid-attenuated inversion recovery (FLAIR, Axial 1.6 × 1.6 × 5.8 mm) scan on a 0.064 T MRI (Hyperfine Inc.). A Montreal Cognitive Assessment (MoCA) score was also collected, with a score ≤ 26 out of 30 indicating impairment. A machine learning algorithm (WMH-Synthseg) demonstrating strong agreement between volumes estimated on conventional and LF-MRI in prior research was used for segmentation.

Results Scans with associated MoCA scores were available in n=135 patients. Scans with hippocampal volumes ≥ 2 standard deviations (SD) away from the mean (7.23 mL, SD = 1.23 mL) were excluded for a final n=130. The average age was 62.4 (SD = 12.4), and the average MoCA score was 23.0 (SD = 4.4). In a linear regression including age, hippocampal volume, and thalamic volume (to control for generalized atrophy), hippocampal volume was significantly associated with MoCA score (p = 0.016) with a standardized coefficient of 0.255. Age and thalamic volume were not significantly associated with MoCA score (p = 0.118 and p = 0.699, respectively).

Conclusions There is a significant, positive relationship between hippocampal volume on LF-MRI and MoCA score in patients with cardiovascular risk factors. Changes in hippocampal volume may mediate cognitive decline due to poor cardiovascular health. Leveraging LF-MRI may allow for the monitoring of these changes in a variety of settings.

Authors/Disclosures
Emma S. Peasley (Yale School of Medicine) PRESENTER	Miss Peasley has nothing to disclose.
Ian P. Johnson	Mr. Johnson has nothing to disclose.
Hailey Brigger	Ms. Brigger has nothing to disclose.
Joel Smith, Clinical Researcher	Mr. Smith has nothing to disclose.
Dheeraj D. Lalwani (Yale University School of Medicine, Department of Neurology)	Mr. Lalwani has nothing to disclose.
Julia Zabinska	Ms. Zabinska has nothing to disclose.
Gordon Sze	Gordon Sze has nothing to disclose.
Sam Payabvash	Sam Payabvash has nothing to disclose.
Annabel Sorby-Adams (Massachusetts General Hospital and Harvard Medical School)	Annabel Sorby-Adams has nothing to disclose.
Jua Iglesias Gonzalez (Martinos Center for Biomedical Imaging)	Jua Iglesias Gonzalez has nothing to disclose.
Matthew Rosen	Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DeepSpin. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chipiron. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Synex Medical. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nanalysis. Matthew Rosen has stock in Hyperfine. Matthew Rosen has stock in Q Bio. Matthew Rosen has stock in Vizma Life Sciences. Matthew Rosen has stock in Intact Data Services. The institution of Matthew Rosen has received research support from Imagion. Matthew Rosen has received intellectual property interests from a discovery or technology relating to health care.
W. T. Kimberly, MD, PhD (Massachusetts General Hospital)	Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Kimberly has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Stryker. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. The institution of Dr. Kimberly has received research support from Alzheimer's Association. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
Adam De Havenon, MD, FAAN (Yale University)	Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care)	Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��